Kuske et al. [24] also reported improved detection of CTCs in nonmetastatic prostate cancer patients by combining 3 independent CTC assays: the CELLSEARCH system, CellCollector, and EPISPOT (an EpCAM-independent enrichment method). The gene discussed is EPCAM; the disease is prostate carcinoma.